OENOTANNIN CELESTE

Tannin complex specially formulated for white and rosé wines without causing hardness

CHARACTERISTICS

OENOTANNIN CELESTE is a tannin complex specially formulated to meet the needs of winemakers who wish to correct a lack of structure in white and rosé wines without causing bitterness and hardness. Its complex formulation enables it to act on the wine's organoleptic balance and thus readjust the structure of dilute wines or wines judged to be thin in the mouth.

OENOLOGICAL PROPERTIES

OENOTANNIN CELESTE is made up of proanthocyanidic tannins with a high degree of polymerisation, which makes it appear less reactive and more supple. Because of this property, this tannin is able to offset the deficient structure of certain wines without causing bitterness, astringency and hardness (see chart below).


*Chart: comparative tasting of a Rosé Pays d'Oc 2015 with and without addition of **OENOTANNIN CELESTE**.*

APPLICATIONS

OENOTANNIN CELESTE can be used in aging or several days before preparing wines for bottling. It can be used with all types of white and rosé wine.

DOSAGE

Recommended dosage:
From 5 to 20 g/hL depending on the structure of the wine and the desired effect.
It is strongly recommended to carry out a few trial runs in order to determine the optimum dosage.

INSTRUCTIONS FOR USE

Dissolve **OENOTANNIN CELESTE** in the wine to be treated (1 kg/20 litres). Add to the wine, and then carry out a light pump-over to ensure thorough mixing.

Precautions for use:
Product for oenological and specifically professional use.
Use in accordance with current regulations.

PACKAGING

500 g

STORAGE

Store unopened, sealed packaging away from light in a dry, odour-free environment.
Once opened use rapidly.

The information provided above is based on our current state of knowledge. This information is non-binding and without guarantee, since the conditions of use are beyond our control. It does not release the user from complying with existing legislation and safety data. This document is the property of SOFRALAB and may not be modified without its agreement.